Quantum-Si reported Q4 2025 revenue of USD 451,000 and gross profit of USD 122,000, for a gross margin of 27%. Q4 net loss was USD 17.6 million, while adjusted EBITDA was negative USD 17.0 million. Operating expenses in Q4 were USD 21.2 million, and cash, cash equivalents and investments in marketable securities totaled USD 215.8 million as of Dec. 31, 2025. For FY 2025, Quantum-Si posted revenue of USD 2.4 million, gross profit of USD 1.2 million and a gross margin of 47%. FY net loss was USD 101.3 million and adjusted EBITDA was negative USD 80.7 million, with total operating expenses of USD 117.3 million. The company said one-time charges tied to legacy litigation matters reserved or settled during FY 2025 totaled USD 18.7 million. On the business side, Quantum-Si said it remains on track with development of its Proteus platform and related R&D programs aimed at expanding proteome coverage and enabling broad PTM analysis capabilities, and announced a Proteus list price of USD 425,000. The company also issued FY 2026 guidance for revenue of approximately USD 1.0 million, adjusted total operating expenses of USD 98.0 million or less, and total cash usage of USD 93.0 million or less, citing strategic actions ahead of the anticipated Proteus launch, including offering a placement program and embedding upgrade credits into Platinum Pro units sold in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum-Si Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260303534840) on March 03, 2026, and is solely responsible for the information contained therein.
Comments